Financial equity research analysts covering Treace Medical Concepts Inc. (NASDAQ: TMCI) maintain varied consensus price targets that reflect cautious optimism alongside near-term market volatility. While targets have adjusted to account for lower elective procedure volumes and shifting product adoption rates, average predictions hover between $4.00 and $5.50 per share, with optimistic high-end estimates reaching up to $9.00 based on the long-term expansion of its innovative 3D bunion correction systems.